Elevated blood sugar and insulin blunt GH release, reducing peptide effectiveness
A complete B12 and nutrient assessment may also be recommended, including laboratory testing
GLP-3 RT is studied for multi-pathway incretin receptor activity linked to glucose regulation and adipose metabolism
Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
This is a great IV if you struggle with drinking water consistently
The body excretes excess water-soluble B12 in urine